8,149 Charles River Laboratories International, Inc. $CRL Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 44.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 10,121 shares of the medical research company’s stock after selling 8,149 shares during the period. Jefferies Financial Group Inc.’s holdings in Charles River Laboratories International were worth $2,986,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CRL. Physician Wealth Advisors Inc. grew its holdings in Charles River Laboratories International by 127.9% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 55 shares during the last quarter. Continuum Advisory LLC purchased a new stake in Charles River Laboratories International in the 2nd quarter worth about $30,000. IFP Advisors Inc raised its position in Charles River Laboratories International by 182.8% in the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after purchasing an additional 106 shares during the period. Compass Wealth Management LLC bought a new stake in Charles River Laboratories International in the third quarter worth about $69,000. Finally, Activest Wealth Management lifted its stake in Charles River Laboratories International by 25.9% in the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after purchasing an additional 57 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the sale, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. The trade was a 28.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James C. Foster sold 33,561 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director owned 31,596 shares of the company’s stock, valued at $9,478,800. This represents a 51.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,352 shares of company stock worth $20,291,281 in the last ninety days. 1.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CRL has been the subject of several recent analyst reports. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research report on Monday, August 10th. Zacks Research downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Robert W. Baird raised their price target on Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a research note on Friday, September 25th. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $180.00 to $310.00 in a report on Thursday, August 6th. Finally, Royal Bank Of Canada upped their price objective on Charles River Laboratories International from $322.00 to $352.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $308.17.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $341.12 on Friday. The company has a 50 day moving average price of $310.31 and a 200-day moving average price of $227.65. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.12 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $379.63. The company has a market capitalization of $16.35 billion, a PE ratio of 374.86, a P/E/G ratio of 3.10 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The firm had revenue of $982.73 million during the quarter, compared to analyst estimates of $960.36 million. During the same quarter in the previous year, the business earned $2.43 earnings per share. Charles River Laboratories International’s quarterly revenue was down 2.2% on a year-over-year basis. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.